Evaro raises $25m to let any consumer brand become a digital healthcare provider
Posted
Evaro, the NHS-licensed digital healthcare platform serving over 2 million patients, today announced it has closed a $25 million Series A funding round led by us at AlbionVC, with participation from Simplyhealth Ventures, Exceptional Ventures, Cornerstone VC, and BBI. The platform already partners with period-tracking app Clue and sexual wellness retailer Lovehoney, embedding prescription services directly into their customer experiences.
The funding will accelerate Evaro’s healthcare-as-a-service model across three markets: consumer brands seeking new revenue streams, healthcare organisations expanding digital capacity, and employers deploying health benefits – all with no technical lift required.
The funding comes as 20.5 million people experienced month-long waits for a GP appointment in 2024, up 60% in seven years. Evaro helps alleviate the burden on the NHS by providing complete regulated healthcare infrastructure – asynchronous consultations allowing speed and discretion of care, remote diagnostics, prescribing, dispensing, and aftercare – that can be embedded into any platform people spend time on within days. For partners, the model creates a new revenue stream with minimal implementation burden – integrations can be completed in as little as 2 weeks – while deepening customer relationships through an expanded health offering. Evaro’s 4.5 Trustpilot rating reflects strong patient satisfaction.
Dr. Thuria Wenbar, CEO and co-founder of Evaro, said: “When a third of people are waiting over a week just to see their GP, it’s time to think through alternative solutions that help people get the care they need while supporting NHS capacity. What we’ve built is infrastructure that allows our partners – brands people already trust – to deliver safe and regulated healthcare for common conditions without having to build a thing. We’re making healthcare as accessible as online banking, and this funding lets us prove that model works at scale.”
Founded in 2018 by emergency physician Dr. Thuria Wenbar and pharmacist researcher Dr. Oskar Wenbar, Evaro serves three distinct markets: consumer brands wanting to generate new revenue; healthcare providers expanding digital capacity for common conditions; and employers deploying health benefits.
The funding will also allow expansion across treatment areas (women’s health, men’s health, and longevity medicine), clinical capabilities such as cutting edge diagnostics and aftercare, and platform development (API-first infrastructure for seamless brand integration).
“We’ve seen embedded finance transform banking, Evaro is now driving the embedded health revolution,” said Christoph Ruedig, Partner at AlbionVC, who joins Evaro’s board. What sets Evaro apart is the depth of their regulatory stack. “Evaro has spent seven years building its infrastructure properly, with deep regulatory credentials. This now allows consumer brands to enter the healthcare space safely, unlocking massive latent demand while relieving pressure on the NHS. We are thrilled to back the team as they define this new category.”
Christoph Ruedig, Partner at AlbionVC
Evaro holds comprehensive regulatory credentials: CQC and GPhC licensed since 2018, with seven active regulatory approvals and NHS integration enabling GP record access for safer prescribing.
Dr. Oskar Wenbar, Chief Medical Officer and co-founder, added: “Patients now expect the same convenience from healthcare that they get from banking or shopping—instant, mobile, on their terms. The technology exists to deliver this for minor conditions, but our system is still stuck requiring appointments, phone calls, physical visits – with no capacity for smart aftercare. We want to solve this, and scale the infrastructure that matches how people actually want to access care in 2026.”
The company aims to serve 10 million patients over the next three years while establishing healthcare-as-a-service as a new category in the UK market. Dr. Thuria Wenbar and Dr. Oskar Wenbar were recently named to The Times’ LDC Top 50 Most Ambitious Business Leaders of 2025.
Sky News has more here.
